AP2013007159A0 - Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase - Google Patents

Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase

Info

Publication number
AP2013007159A0
AP2013007159A0 AP2013007159A AP2013007159A AP2013007159A0 AP 2013007159 A0 AP2013007159 A0 AP 2013007159A0 AP 2013007159 A AP2013007159 A AP 2013007159A AP 2013007159 A AP2013007159 A AP 2013007159A AP 2013007159 A0 AP2013007159 A0 AP 2013007159A0
Authority
AP
ARIPO
Prior art keywords
tropomyosin
pyrrolo
inhibitors
pyrimidine derivatives
related kinase
Prior art date
Application number
AP2013007159A
Other languages
English (en)
Inventor
Mark David Andrews
Karl Richard Gibson
Kiyoyuki Omoto
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007159(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AP2013007159A0 publication Critical patent/AP2013007159A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
AP2013007159A 2011-04-05 2012-03-22 Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase AP2013007159A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05
PCT/IB2012/051363 WO2012137089A1 (fr) 2011-04-05 2012-03-22 Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine

Publications (1)

Publication Number Publication Date
AP2013007159A0 true AP2013007159A0 (en) 2013-10-31

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007159A AP2013007159A0 (en) 2011-04-05 2012-03-22 Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase

Country Status (31)

Country Link
US (2) US8846698B2 (fr)
EP (1) EP2694509B1 (fr)
JP (1) JP5595616B2 (fr)
KR (1) KR20130133905A (fr)
CN (1) CN103534257A (fr)
AP (1) AP2013007159A0 (fr)
AR (1) AR085852A1 (fr)
AU (1) AU2012238369A1 (fr)
BR (1) BR112013025792A2 (fr)
CA (1) CA2832291C (fr)
CL (1) CL2013002821A1 (fr)
CO (1) CO6801740A2 (fr)
CR (1) CR20130470A (fr)
CU (1) CU20130129A7 (fr)
DO (1) DOP2013000221A (fr)
EA (1) EA201391239A1 (fr)
EC (1) ECSP13013009A (fr)
ES (1) ES2581848T3 (fr)
GE (1) GEP20156417B (fr)
GT (1) GT201300236A (fr)
IL (1) IL228590A0 (fr)
MA (1) MA35024B1 (fr)
MX (1) MX2013011612A (fr)
NI (1) NI201300103A (fr)
PE (1) PE20141050A1 (fr)
SG (1) SG193513A1 (fr)
TN (1) TN2013000394A1 (fr)
TW (1) TWI443101B (fr)
UA (1) UA108926C2 (fr)
UY (1) UY34004A (fr)
WO (1) WO2012137089A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150007349A (ko) * 2012-05-11 2015-01-20 애브비 인코포레이티드 Nampt 억제제
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
US20150250785A1 (en) * 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR122019024759B1 (pt) 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
CA2903431C (fr) 2013-03-14 2022-12-06 Kalyra Pharmaceuticals, Inc. Composes analgesiques bicyclopentanes
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP3080072A4 (fr) 2013-12-12 2017-07-19 Kalyra Pharmaceuticals, inc. Composés d'alkyle bicyclique et synthèse
EP3083602A1 (fr) 2013-12-20 2016-10-26 Pfizer Limited Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine
WO2015112754A1 (fr) * 2014-01-24 2015-07-30 Abbvie Inc. Dérivés furo-3-carboxamide et méthodes d'utilisation
SI3102555T1 (sl) * 2014-02-05 2021-11-30 VM Oncology LLC Sestavki spojin in njihove uporabe
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
WO2015143654A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
EP3140298A1 (fr) * 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
JP6833677B2 (ja) * 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
TWI780438B (zh) 2014-12-18 2022-10-11 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
EP3239150B1 (fr) * 2014-12-24 2020-02-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017220516A1 (fr) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Dérivés de triazolo[4,5-d]pyrimidine
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
AU2018269755B2 (en) 2017-05-15 2022-06-16 Recurium Ip Holdings, Llc Analgesic compounds
WO2018237134A1 (fr) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomérisme pour une sélectivité améliorée des inhibiteurs de kinase
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
WO2019189945A1 (fr) * 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (fr) * 2018-10-23 2020-04-30 Lupin Limited Intermédiaire de ribociclib et son procédé de préparation
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
EP4357347A1 (fr) * 2021-06-21 2024-04-24 Henan Medinno Pharmaceutical Technology Co., Ltd. Composé inhibiteur de la kinase trk et son utilisation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
PL335685A1 (en) * 1997-03-19 2000-05-08 Basf Ag Pyrrole[2,3-d]pyrimidines and their application as inhibitors of tyrosine kinase
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
WO2005066132A1 (fr) 2004-01-07 2005-07-21 Astrazeneca Ab Agents therapeutiques i
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP4842929B2 (ja) * 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
EP1885723A2 (fr) * 2005-05-17 2008-02-13 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
MX2009006688A (es) 2006-12-21 2009-06-30 Plexxikon Inc Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
WO2008135826A2 (fr) 2007-05-03 2008-11-13 Pfizer Limited Dérivés de la pyridine
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
CA2695004C (fr) 2007-07-17 2016-01-19 Plexxikon, Inc. Composes et procedes pour la modulation des kinases et leurs indications
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2009257635A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
PT2385938E (pt) 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
MX2013011612A (es) 2013-10-17
JP2014510131A (ja) 2014-04-24
ES2581848T3 (es) 2016-09-07
ECSP13013009A (es) 2013-12-31
GT201300236A (es) 2015-08-04
NI201300103A (es) 2014-02-12
NZ615557A (en) 2014-08-29
JP5595616B2 (ja) 2014-09-24
CU20130129A7 (es) 2014-01-29
IL228590A0 (en) 2013-12-31
EA201391239A1 (ru) 2014-03-31
BR112013025792A2 (pt) 2018-04-24
UY34004A (es) 2012-11-30
US20140364415A1 (en) 2014-12-11
AR085852A1 (es) 2013-10-30
CR20130470A (es) 2013-10-16
CL2013002821A1 (es) 2014-02-21
UA108926C2 (ru) 2015-06-25
CA2832291C (fr) 2015-12-01
SG193513A1 (en) 2013-10-30
MA35024B1 (fr) 2014-04-03
US20120258950A1 (en) 2012-10-11
CN103534257A (zh) 2014-01-22
EP2694509A1 (fr) 2014-02-12
CO6801740A2 (es) 2013-11-29
TN2013000394A1 (fr) 2015-01-20
CA2832291A1 (fr) 2012-10-11
KR20130133905A (ko) 2013-12-09
TWI443101B (zh) 2014-07-01
US8846698B2 (en) 2014-09-30
AU2012238369A1 (en) 2013-10-03
GEP20156417B (en) 2015-12-25
TW201302757A (zh) 2013-01-16
WO2012137089A1 (fr) 2012-10-11
PE20141050A1 (es) 2014-08-30
DOP2013000221A (es) 2014-03-16
EP2694509B1 (fr) 2016-05-18

Similar Documents

Publication Publication Date Title
AP2013007159A0 (en) Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
HUS2200003I1 (hu) Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
HK1192248A1 (en) Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors [43-d]
HK1222659A1 (zh) 吡咯並 嘧啶衍生物，它們的製備方法和它們作爲激酶抑制劑的用途
ZA201306545B (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of betasecretase (bace)
EP2608669A4 (fr) Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
HK1189229A1 (zh) 三環吡咯並衍生物、它們的製備方法和它們作為激酶抑制劑的應用
IL217414A0 (en) SUBSTITUTED PYRAZOLO[1, 5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
HK1189223A1 (zh) 用作β分泌酶 抑制劑的 -二氫-吡咯並 吡嗪- -基胺衍生物
EP2661437A4 (fr) Dérivés de 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine comme inhibiteurs de fak/pyk2
EP2525659A4 (fr) Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
EP2739627A4 (fr) Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
HK1209740A1 (en) Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use --[23-d] pi3k
PL2694513T3 (pl) Pochodne pirazolopirymidynowe
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
EP2523552A4 (fr) Pyrazolo[1,5-a]pyrimidines comme inhibiteurs de mark